Amir Dori

Distribution of the zinc transporter ZnT-1 in comparison with chelatable zinc in the mouse brain

Zinc maintains a diverse array of functions in the mammalian central nervous system as a key component of numerous enzymes, via its role in the activation of transcription factors, and as a neuroregulator, modulating neuronal receptors such as N‐methyl‐D‐aspartate and γ‐aminobutyric acid. Zinc has a dark side, however, with massive influx of Zn2+ to neurons considered to be a key factor in neuronal death secondary to ischemia and seizure. Several different putative zinc transporters, ZnT‐1–4, have recently been identified and characterized. Among them, ZnT‐1 has been suggested to play a key role in reducing cellular Zn2+ toxicity. In the present study, we describe the regional and cellular distribution of ZnT‐1 in the adult mouse brain using an antibody raised against the C‐terminal domain of mouse ZnT‐1. The distribution of ZnT‐1 was compared to that of chelatable Zn2+, visualized by means of neoTimm histochemistry or N‐(6‐methoxy‐8‐quinolyl)‐p‐toluene‐sulfonamide (TSQ) histofluorescence. Extracts from various brain regions specifically stained a 60‐kDa peptide corresponding to the expected molecular weight of ZnT‐1. The expression of ZnT‐1 was highest in the cerebral cortex and cerebellum, moderate in the hippocampus, hypothalamus, and olfactory bulb, and lowest in the striatum and septum. In brain sections, ZnT‐1‐immunoreactive neurons, in particular principle neurons, in the somatosensory cortex, hippocampus, and olfactory bulb, were closely related to synaptic Zn2+. Robust ZnT‐1 immunoreactivity was also observed in cerebellar Purkinje cells. Although the function of the protein in these cells is unclear, in the forebrain, ZnT‐1 is strikingly present in cells and regions where significant Zn2+ homeostasis is required. This finding suggests a protective role for neuronal ZnT‐1 in the context of both normal and pathophysiological activity. J. Comp. Neurol. 447:201–209, 2002.

SC35 promotes sustainable stress-induced alternative splicing of neuronal acetylcholinesterase mRNA

Long-lasting alternative splicing of neuronal acetylcholinesterase (AChE) pre-mRNA occurs during neuronal development and following stress, altering synaptic properties. To explore the corresponding molecular events, we sought to identify mRNAs encoding for abundant splicing factors in the prefrontal cortex (PFC) following stress. Here we show elevated levels of the splicing factor SC35 in stressed as compared with naïve mice. In cotransfections of COS-1 and HEK293 cells with an AChE minigene allowing 3′ splice variations, SC35 facilitated a shift from the primary AChE-S to the stress-induced AChE-R variant, while ASF/SF2 caused the opposite effect. Transfection with chimeric constructs comprising of SC35 and ASF/SF2 RRM/RS domains identified the SC35 RRM as responsible for AChE mRNAs alternative splicing. In poststress PFC neurons, increased SC35 mRNA and protein levels coincided with selective increase in AChE-R mRNA. In the developing mouse embryo, cortical progenitor cells in the ventricular zone displayed transient SC35 elevation concomitant with dominance of AChE-R over AChE-S mRNA. Finally, transgenic mice overexpressing human AChE-R, but not those overexpressing AChE-S, showed significant elevation in neuronal SC35 levels, suggesting a reciprocal reinforcement process. Together, these findings point to an interactive relationship of SC35 with cholinergic signals in the long-lasting consequences of stress on nervous system plasticity and development.

ARP, the cleavable C-terminal peptide of “readthrough” acetylcholinesterase, promotes neuronal development and plasticity

The mammalian acetylcholinesterase (ACHE) gene gives rise to diverse enzymatically active proteins with three different carboxyl termini. In the brain, the normally rare readthrough AChE-R monomer accumulates under embryonic development and in adults following psychological stress, head injury, or exposure to AChEs. In the prenatal developing cortex, its unique C-terminal peptide ARP associates with radial glial fibers supporting neuronal migration. In contrast, the major synaptic AChE-S variant appears in the migrating neurons themselves. Moreover, antisense suppression of AChE-R attenuates neuronal migration, allowing increased proliferation of neuronal progenitors. In the adult brain, neuronal AChE-R is either secreted or accumulates intraneuronally, where it interacts through ARP with the scaffold protein RACK1 and activated PKC-ßII. This associates with increased PKC-ßII activity, which shuttles to submembranal clusters (e.g., in hyperactivated hippocampal neurons). Cleavage yields the AChE-R-specific C-terminal peptide, including immunopositive ARP. Importantly, intrahippocampal injection of synthetic ARP was followed by its efficient neuronal penetration and retrograde transport into cortical and basal nuclei neurons. Moreover, ARP-injected mice presented increased stress-induced contextual fear, inhibitable by antisense suppression of AChE-R mRNA. Together, our findings point at the cleavable ARP peptide as a key regulator of neuronal development and plasticity and suggest its use as a drug target and/or research and therapeutic tool.

Prolonged systemic inflammation persistently modifies synaptic plasticity in the hippocampus: modulation by the stress hormones

Transient systemic inflammation has been shown to cause altered behavior both in humans and in laboratory animals through activation of microglia and heightened level of cytokines detected in the brain and in the body. Furthermore, both activated microglia and the increased cytokines level have been associated with the sudden clinical deterioration in demented people or in aged patients upon systemic inflammation. Whilst it is increasingly becoming clear the role of transient systemic inflammation in promoting dementia in aged individuals, it is still a matter of debate whether prolonged systemic inflammation might persistently modify the brain. In this study, we examined the influence of a systemic long term inflammatory event on synaptic plasticity. We report that while a short exposure to LPS produces transient deficit in long term potentiation (LTP) expression, systemic prolonged inflammation impairs LTP in slices of animals previously primed by a Complete Freund’s adjuvant injection. Interestingly, steroids are able to modulate this effect: whereas glucocorticosteroid (GR) activation further reduces LTP, mineralocorticosteroid receptors (MR) activation promotes the full recovery of LTP. We believe that this research advances the current understandings on the role of the immune system in the onset and progression of cognitive deficits following long lasting systemic inflammation, and proposes possible insights on future strategies in order to prevent early dementia in these predisposed individuals.

Strain and regional dependence of alternate splicing of acetylcholinesterase in the murine brain following stress or treatment with diisopropylfluorophosphate.

Induction of the rare readthrough variant of acetylcholinesterase (AChE-R) by an acetylcholinesterase (AChE) inhibitor or by stress was tested in four mouse strains that differ in their behavioural profiles on tests of anxiety and depression. BALB/C, C57Bl/6, C3H/He and CD-1 mouse strains were tested in the elevated plus maze in two sessions, separated by 48h. All strains, except CD-1, showed the expected reduction in open arm exploration on the second session. BALB/C and C3H mice spent a greater proportion of the time in the open arms on the first exposure, but spent more time immobile in the maze compared to the CD1 and C57 strains. Immobility was attenuated upon the second exposure in all strains, except the BALB/C mice. Real-time PCR was used to investigate regional and strain differences in induction of AChE-R mRNA following four daily injections of diisopropylfluorophosphate (DFP) (.1mg/kg). AChE-R induction was found in the frontal cortex, but not in amygdala, hippocampus or striatum of CD-1 mice. Nor was there AChE-R induction in the brains of the inbred strains. Four daily sessions of swim stress were used to investigate stress-induced induction of AChE-R. BALB/C mice showed significantly more immobility in the forced swim test (FST) compared to the other strains. FST did not induce AChE-R mRNA in any brain region tested; however, AChE-R mRNA expression in the frontal cortex was negatively correlated with immobility in the FST.

Sarcoidosis Presenting as “Corset-like” Myelopathy: A Description of Six Cases and Literature Review

Sarcoidosis of the spinal cord is rare, even more so as the initial presentation of the disease. We describe six cases of spinal cord sarcoidosis and delineate a distinguishing feature which may allow for a timely diagnosis. All patients were admitted with complaints of a “corset-like” pressure in the lower chest and later developed cranial nerve palsies (two patients), parasthesias/paraparesis (two patients), fever of unknown origin (one patient), and bilateral proptosis (one patient). Serological tests, immunological screening, cerebrospinal fluid (CSF) analysis, bacteriological and viral testing were performed in all patients. Spinal and cerebral MRI, high-resolution computed tomography (HRCT) of the chest and gallium scan suggested the diagnosis of neurosarcoidosis of the spine while a biopsy of mediastinal lymph nodes, extra-ocular muscles, or spinal cord confirmed it. CSF showed inflammatory signs in 66% of patients and serum ACE levels were increased in a similar fraction. MRI revealed a gadolinium-enhanced thickening of the cord at the thoracic level in three patients whereas three other patients had normal spinal MRI despite similar symptoms. The presence of mediastinal lymphadenopathy on HRCT of the chest suggested the diagnosis in a third of patients. Patients were treated with steroid, immunosuppressive therapy and/or biologic therapies, with complete resolution in one case, improvement in four, and a somewhat deteriorating course, with development of spinal cord atrophy in the final case. As spinal cord involvement of sarcoidosis is extremely rare, making the diagnosis in the absence of systemic disease is challenging. The cases herein described suggest that sensory disturbance in a “corset-like” distribution may be indicative of neurosarcoidosis, especially when accompanied by extra-axial involvement such as cranial nerve palsies. This should prompt an evaluation for systemic involvement, keeping in mind that serum ACE and chest radiographs may be normal in the presence of primarily CNS-limited disease.

Neuromuscular Therapeutics by RNA‐Targeted Suppression of ACHE Gene Expression

Abstract:  RNA‐targeted therapeutics offers inherent advantages over small molecule drugs wherever one out of several splice variant enzymes should be inhibited. Here, we report the use of Monarsen, a 20‐mer acetylcholinesterase‐targeted antisense agent with three 3′‐2′o‐methyl‐protected nucleotides, for selectively attenuating the stress‐induced accumulation of the normally rare, soluble “readthrough” acetylcholinesterase variant AChE‐R. Acetylcholine hydrolysis by AChE‐R may cause muscle fatigue and moreover, limit the cholinergic anti‐inflammatory blockade, yielding inflammation‐associated pathology. Specific AChE‐R targeting by Monarsen was achieved in cultured cells, experimental animals, and patient volunteers. In rats with experimental autoimmune myasthenia gravis, oral delivery of Monarsen improved muscle action potential in a lower dose regimen (nanomolar versus micromolar), rapid and prolonged manner (up to 72 h versus 2–4 h) as compared with the currently used small molecule anticholinesterases. In central nervous system neurons of both rats and cynomolgus monkeys, systematic Monarsen treatment further suppressed the levels of the proinflammatory cytokines interleukin‐1 (IL‐1) and IL‐6. Toxicology testing and ongoing clinical trials support the notion that Monarsen treatment would offer considerable advantages over conventional cholinesterase inhibitors with respect to dosing, specificity, side effects profile, and duration of efficacy, while raising some open questions regarding its detailed mechanism of action.

Myovascular innervation: Axon loss in small‐fiber neuropathies

Vascular denervation occurs in some neuropathies, but measurement of small perivascular axons has been difficult.

Acetylcholinesterase inhibitor pretreatment alters stress-induced expression of acetylcholinesterase transcripts in the mouse brain.

The role of the rare soluble splice variant of acetylcholinesterase (AChE-R) in anxiety behavior was assayed using the elevated plus maze (EPM). The effects of pretreatment with restraint stress and the acetylcholinesterase inhibitor diisopropylfluorophosphate (DFP) were tested, as these treatments are known to enhance the expression of AChE-R in several brain regions. Mice from the CD-1 outbred and C57BL/6 inbred strains were randomly assigned to seven treatment groups: homecage control, elevated plus maze without pretreatment, 3 days restraint stress or 3 days pretreatment with saline or one of three doses of DFP, for a total of 14 groups. All mice, except homecage controls, were tested twice on the elevated plus maze. AChE-R transcript expression was increased following elevated plus maze stress in hippocampus and amygdala, but not in the prefrontal cortex of CD-1 and not in C57BL/6 mice. Saline-injected C57BL/6 mice had reduced expression of AChE-R transcripts compared to untreated C57 BL/6 mice. DFP pretreatment reversed the stress-induced changes, increased AChE-R transcripts in CD-1 mice. AChE-R expression in the striatum and amygdala were positively correlated with anxiety in the EPM.

Differential long term effects of early diisopropylfluorophosphate exposure in Balb/C and C57Bl/J6 mice

The long‐term effect of postnatal administration of a sub‐toxic dose of the irreversible acetylcholinesterase inhibitor diisopropylfluorophosphate (DFP) on depression and anxiety behavior was compared in two strains of inbred mice. C57BL/6J and Balb/C mice were injected for 7 consecutive days with either 1 mg/kg DFP or saline on postnatal days 14–20. Mice were tested at age 3–4 months for initial and learned anxiety using double‐exposure elevated plus maze and to a novel enclosed environment. Depression was assayed using the sweet preference model of anhedonia and the forced swim test for despair. Postnatal DFP pretreatment led to less activity and more immobility in the elevated plus maze in both mouse strains in the first session. The effect was attenuated in the second session in the C57BL/6J strain but not the Balb/C strain. DFP did not affect the sweet preference or forced swim tests, suggesting a dissociation between the long‐term effects of DFP on immobility in the context of approach‐avoidance conflict (elevated plus maze) versus despair (forced swim).